Last $1.10 USD
Change Today 0.00 / 0.00%
Volume 0.0
POLXF On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 07/21/14 All times are local (Market data is delayed by at least 15 minutes).

polydex pharmaceuticals ltd (POLXF) Snapshot

Open
$1.04
Previous Close
$1.10
Day High
$1.10
Day Low
$1.04
52 Week High
11/8/13 - $1.50
52 Week Low
03/12/14 - $0.68
Market Cap
3.4M
Average Volume 10 Days
200.0
EPS TTM
$0.13
Shares Outstanding
3.1M
EX-Date
--
P/E TM
8.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for POLYDEX PHARMACEUTICALS LTD (POLXF)

Related News

No related news articles were found.

polydex pharmaceuticals ltd (POLXF) Related Businessweek News

No Related Businessweek News Found

polydex pharmaceuticals ltd (POLXF) Details

Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market; and manufacture of bulk pharmaceutical intermediates for the veterinary pharmaceutical industry worldwide. The company primarily offers Dextran and derivative products, including Iron Dextran, a derivative of Dextran used for the treatment of anemia in pigs; and Dextran Sulphate, a specialty chemical derivative of Dextran used in research applications by the pharmaceutical industry and other centers of chemical research. Polydex Pharmaceuticals Limited company sells its Iron Dextran primarily to independent distributors and wholesalers in Europe, the Far East, South America, and Canada; and Dextran Sulphate to the independent distributors and wholesalers in the United States and Europe for analytical applications. It also develops Ushercell, a high molecular weight Cellulose Sulphate envisioned for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies; and Usherdex 4 for the treatment of Cystic fibrosis, a genetic disease. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. The company was founded in 1966 and is based in Toronto, Canada.

21 Employees
Last Reported Date: 04/21/14
Founded in 1966

polydex pharmaceuticals ltd (POLXF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

polydex pharmaceuticals ltd (POLXF) Key Developments

Polydex Pharmaceuticals Ltd. Announces Earnings Results for the First Quarter Ended April 30, 2014

Polydex Pharmaceuticals Ltd. announced earnings results for the first quarter ended April 30, 2014. For the quarter, the company reported sales of $1,412,982 against $1,440,144 a year ago. Net income was $74,595 against $271,516 a year ago. Diluted income per share was $0.02 against $0.08 a year ago. EBITDA was $123,984. Sales in the first quarter remained strong, although slightly below the same period last year due to an extraordinary order from an ongoing customer in the first quarter of last year.

Polydex Pharmaceuticals Ltd. Reports Earnings Results for the Year Ended January 31, 2014

Polydex Pharmaceuticals Ltd. reported earnings results for the year ended January 31, 2014. For the year, the company reported sales of $5,963,784 against $5,192,969 a year ago. Net income was $658,922 or $0.20 per diluted share against net loss of $422,849 or $0.13 per diluted share a year ago. EBITDA reversed from a loss of $200,463 in fiscal 2013 to a gain of $837,645. EBITDA income per diluted share was $0.25 against LBITDA loss per diluted share of $0.06 a year ago.

Polydex Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2013

Polydex Pharmaceuticals Ltd. reported earnings results for the third quarter and nine months ended October 31, 2013. For the quarter, the company reported sales of $1,319,100 against $1,385,226 a year ago. Net income was $46,300 or $0.01 per basic and diluted share against net loss of $133,584 or $0.04 per basic and diluted share a year ago. For the nine months, the company reported sales of $4,625,497 against $3,696,826 a year ago. Net income was $518,594 or $0.15 per diluted share against net loss of $360,550 or $0.11 per diluted share a year ago. EBITDA (earnings before interest, taxes, depreciation and amortization) was increased to $656,530 compared to LBITDA of $144,329 for the same period in the previous year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
POLXF:US $1.10 USD 0.00

POLXF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for POLXF.
View Industry Companies
 

Industry Analysis

POLXF

Industry Average

Valuation POLXF Industry Range
Price/Earnings 8.2x
Price/Sales 0.6x
Price/Book 1.1x
Price/Cash Flow 7.2x
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact POLYDEX PHARMACEUTICALS LTD, please visit www.polydex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.